Incyte sells Jakafi, the ruxolitinib franchise for myelofibrosis and polycythemia vera, and has been building a second leg in dermatology with Opzelura (ruxolitinib cream) and its oncology pipeline. Its moat rests on a single molecule with multiple approved indications and a patent-protected commercial base still generating the bulk of revenue. Revenue growth of 37.7% and a 41.9% operating margin show the newer launches now carrying weight alongside the legacy franchise, which matters because the company has long been judged on its Jakafi exclusivity runway. The stock trades at 14.2x trailing and 12.8x forward earnings, a modest multiple for a business compounding this fast with a 30.7% return on equity. The thesis deserves a deeper look if the Opzelura ramp and pipeline readouts keep pace with the growth in the numbers, since the forward multiple leaves little room for a stumble.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 20 Oct 2026, 16:04 CEST | Fair value | $113 | $199 | $113 |
| 20 Oct 2026, 16:04 CEST | Rating | Fairly valued | first publication | $113 |
| 16 Oct 2026, 00:00 CEST | Fair value | $199 | $190 | $112 |
| 11 Oct 2026, 00:00 CEST | Fair value | $190 | $97.13 | $113 |
| 7 Oct 2026, 00:00 CEST | Fair value | $97.13 | $98.57 | $114 |
| 1 Oct 2026, 00:00 CEST | Fair value | $98.57 | $101 | $123 |
| 28 Sept 2026, 00:00 CEST | Fair value | $101 | $102 | $124 |
| 26 Sept 2026, 00:00 CEST | Fair value | $102 | $104 | $124 |
| 24 Sept 2026, 00:00 CEST | ACCE price target | $142 | first publication | $127 |
| 24 Sept 2026, 00:00 CEST | Fair value | $104 | $103 | $127 |
Answered from Incyte Corp. Common Stock fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| INCY Incyte Corp. Common Stock | $115.71 | $113 | 2% above | 14.9x | 30.7% | 96 | 92 |
| GMAB.CO Genmab A/S | kr 2654.00 | kr 3543 | 25% below | 32.7x | 14.0% | 78 | 68 |
| GMAB Genmab A/S ADS | $40.00 | $55 | 27% below | 31.3x | 14.0% | 78 | 68 |
| BNTX BioNTech SE American Depositary Share | $89.67 | - | - | - | -9.3% | 47 | 32 |
| ROIV Roivant Sciences Ltd. Common Shares | $37.45 | - | - | - | -8.5% | 31 | 41 |
| INSM Insmed Incorporated Common Stock | $95.06 | - | - | - | -87.2% | 38 | 32 |
| ALNY Alnylam Pharmaceuticals Inc. Common Stock | $227.28 | $144 | 58% above | 37.8x | 96.6% | 79 | 49 |
Where INCY ranks against its sector peers on each metric.